|
Found 30 result(s) FROM 1963 pages containing the term 'TNF-inhibitors'.
Tuesday Apr 28, 2009
RA Patients Could Be Hard Hit By Swine Flu
Rheumatologists must be vigilant in looking for signs and symptoms of the swine flu in their immunocompromised patients—including those on TNF-inhibitors...
Thursday Nov 13, 2008
Il-6 Blockade Helps Move RA Patients TOWARD Remission
Interleukin-6 blockade with tocilizumab (Actemra®), when combined with conventional DMARDs, safely and effectively reduces rheumatoid arthritis joint and systemic symptoms in patients were not helped by DMARDs alone...
Wednesday Aug 27, 2008
Pivotal Humira Trial Shows Durable Benefit in Juvenile Rheumatoid Arthritis
The pivotal trial of adalimumab (Humira®) shows durable, safe efficacy for up to 2 years for children with polyarticular JRA and positions the TNF-inhibitor as the reasonable second-line drug to add if methotrexate does not provide sufficient disease control...
Monday Aug 18, 2008
Power Doppler Ultrasound Measures Response to TNF-blockers in RA
Power doppler ultrasonographic monitoring may help measure response to TNF-blockers as well as predict X-ray progression in rheumatoid arthritis (RA) patients…
Wednesday Jun 18, 2008
Anti-TNF Gene Therapy Appears Safe, May Reduce Pain, Swelling in RA Joints
Researchers report that transferring a TNF-antagonist gene into the joint is safe, may reduce pain and swelling in patients with inflammatory arthritis...
Monday Jun 16, 2008
Phase III Data Show Golimumab Efficacy in MTX-Resistant, TNF-Pretreated, Untreated RA
Data from the phase III GO-FORWARD and GO-BEFORE studies show that subcutaneous golimumab improves symptoms, function in RA patients after MTX, anti-TNF failure...
Thursday Jan 17, 2008
Elan, Biogen Idec Gain US FDA Approval of Tysabri® for Treatment of Moderate-to-Severe Crohn's Disease
Elan Corp, plc and Biogen Idec announced the approval of a supplemental Biologics License Application for Tysabri® (natalizumab) for inducing and maintaining clinical response and remission in adult patients with active moderate-to-severe Crohn's disease...
Tuesday Jan 15, 2008
Three More Cases of Significant Neutropenia Lead to Recommendation for Routine CBC Monitoring
Three more cases of significant neutropenia in rheumatoid arthritis (RA) and psoriatic arthritis patients treated with etanercept lead to a recommendation for regular monitoring of complete blood counts (CBC)...
Wednesday Jan 02, 2008
Experts Question Use of TNF Blockers for Sciatica Caused by Disc Herniation
The jury is still out on whether TNF-blockers have a role in treating sciatica induced by disc herniation...
Monday Nov 19, 2007
TNF-Blocker Plus MTX Slashes Heart Risk in RA
Combination therapy with a TNF-inhibitor plus MTX slashes heart attack risk by 80% in rheumatoid arthritis (RA) patients...
Tuesday Nov 06, 2007
Flu Shots Work for Patients on TNF-Inhibitors
TNF inhibitors reduce response to influenza vaccination, but about 80% of RA patients still develop protective titers after a single vaccine dose...
Monday Jul 30, 2007
Long-term MTX or TNF-Inhibitors Do Not Increase EBV Load in RA Patients
The immunosuppressant effects of long-term use of methotrexate or TNF-inhibitors by rheumatoid arthritis (RA) patients do not lead to increased Epstein-Barr virus load...Balandraud N, et al. Arthritis Care Res. 2007;57:762-767.
Monday Jun 18, 2007
Immediate Switch From TNF-Inhibitors To Abatacept Safe in RA Patients
A washout is not needed when switching from a TNF-inhibitor to abatacept...
Saturday Jun 16, 2007
Certolizumab, First PEGylated TNF-Blocker, May Surpass Older Drugs in Efficacy, Safety
When used with methotrexate, certolizumab pegol (Cimzia) may move rheumatoid arthritis (RA) patients into remission more quickly than currently available TNF-blockers...
Friday Jun 15, 2007
Has the Increasing Use of Anti-TNF Drugs Led to a Rise in Cases of Drug-Induced Lupus? Study Says Yes
The increasing use of TNFα inhibitors to treat rheumatic, digestive, and cutaneous diseases has led to a corresponding rise in the number of cases of drug-induced lupus...
Friday Jun 15, 2007
Two Thirds of Gout Patients Receiving No, or Not Enough Treatment
A number of new treatment options for gout are available, but the major clinical problem is that even after gout diagnosis, only about one third of patients receive urate-lowering therapy...
Wednesday Jun 13, 2007
Stopping AS May Require Earlier Use of TNF-Inhibitors
Inflammation in AS stops once the subchondral bone is eroded and the bone/cartilage interface disappears, so preventing bone erosion and syndesmophyte formation is likely to require early anti-inflammatory treatment, including TNF-inhibitors...
Thursday Apr 26, 2007
Local Gene Therapy for RA Intra-articular Anti-TNF Gene Transduction Reduces Joint Inflammation in RA Animal Model
An anti-TNF gene therapy vector carried by an adeno-associated retrovirus vector and injected into inflamed joints successfully reduced joint inflammation and levels of inflammatory markers in an animal model of RA...
Wednesday Apr 18, 2007
Death Forces Early Termination of Study of Infliximab in Systemic Vasculitis
Adverse events, including one death among nine patients treated, forced early termination of infliximab trial in systemic vasculitis...
Thursday Apr 05, 2007
More Evidence Points Toward Safety of Anti-TNF Drugs During Pregnancy
Three recent case reports add to an accumulating body of evidence that the TNF-blockers are safe during pregnancy, but one new report is far from the final word on the issue...
Thursday Mar 22, 2007
New Studies Urge Closer Monitoring for JIA-Related Uveitis, TNF-Inhibitors Effective For Difficult Cases
New studies report that uveitis occurs in up to 20% of JIA patients, that TNF-inhibitors may be effective in hard-to-treat cases, and that close monitoring for uveitis should continue even during arthritis remissions...
Friday Mar 09, 2007
TNF-Inhibitors Cut Cancer, Cardiac, Overall Mortality in RA Patients
A comparison of two nationwide databases shows that RA patients treated with TNF-inhibitors have lower mortality from all causes than RA patients not taking these drugs...
Thursday Jan 25, 2007
Anti-Infliximab Antibodies Linked to Nonresponse in AS
New research outlines some drawbacks and limitations in the use of TNF-inhibitors among patients with ankylosing spondylitis (AS) and other forms of spondylarthritis...
Tuesday Jan 09, 2007
Small Study Highlights Role for Etanercept in Rheumatological Manifestations of HCV
Etanercept seems to be safe and effective for the treatment of rheumatological manifestations associated with hepatitis virus C, but more studies are needed before firm conclusions can be drawn...
Thursday Oct 19, 2006
Access to TNF-Blockers Severely Limited in UK
Access to TNF-inhibitor treatment is limited even for British RA patients who meet official guidelines for treatment, and is even more limited for patients with psoriatic arthritis or ankylosing spondylitis ... Kay, LJ, et al. Rheumatology. 2006 Oct 11; [Epub ahead of print].
Friday Apr 14, 2006
Low Risk of Serious Infections With Infliximab When Used at Approved Dose of 3 mg/kg
New research suggests that the risk of serious infections in RA patients given the approved infliximab dose of 3 mg/kg plus methotrexate (MTX) is similar to the risk among patients receiving MTX alone... Westhovens R, et al. Arthritis Rheum. 2006;54:1075-1086.
Tuesday Feb 21, 2006
TNF Inhibitors May Benefit Refractory Dermatomyositis and Polymyositis
Tumor necrosis factor-alpha inhibitors may be useful for the treatment of some cases of refractory dermatomyositis and polymyositis... Efthimiou P, et al. Ann Rheum Dis. [serial online]. February 13, 2006; doi.10.1136/ard.2005.048744.
Thursday Nov 17, 2005
Three Novel and Distinct Agents Show Promise in RA
Three promising new rheumatoid arthritis (RA) drugs—including an oral small-molecule inhibitor that targets a novel adenosine receptor (AR) and a new anti-tumor necrosis factor-alpha (TNF-α) agent—may soon augment the rheumatologist's ever-expanding armamentarium... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Friday Mar 25, 2005
Genetic Variation Helps Predict Response to Etanercept in Rheumatoid Arthritis
As the FDA takes action to speed the clinical application of pharmacogenetics, the possibility of personalized medicine for RA patients got a boost from a new study showing that a polymorphism in TNF-α affects the response to etanercept therapy...Kang CP, et al. Rheumatology. 2005;44:547-552.
Tuesday Mar 22, 2005
IL-6 Blocker "Promising" in Systemic Onset Juvenile Idiopathic Arthritis
Small study demonstrating efficacy and safety of MRA in juvenile arthritis, combined with promising results in treatment of other conditions, suggests that IL-6 inhibitors may play an important role in controlling inflammatory disease...Yokota S, et al. Arthritis Rheum. 2005;52:818-825.
|
